PMVP

PMV Pharmaceuticals, Inc.

1.28 USD

Last updated Sep 4, 20:15 UTC

Yesterday HIGH

$1.29

Yesterday LOW

$1.2

52w HIGH

$1.88

52w LOW

$1.02

EPS

-0.34

PE

-3.76

Next Earnings

Nov 11, 2026

Overview News Government Trades Fundamentals

PMV Pharmaceuticals, Inc. stock is up 9.4% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 6 September’s closed higher than August.

Avi Kapoor

Tue Sep 1, 2026

Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket

Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of 27 cents per
Benzinga Newsdesk

Tue Sep 1, 2026

Reported Earlier, PMV Pharmaceuticals Priced An Underwritten Public Offering Of 22.055M Common Shares, Pre-funded Warrants For Up To 19.9M Shares, And Accompanying Warrants To Purchase Up To 41.955M Common Shares
Benzinga Newsdesk

Mon Aug 31, 2026

PMV Pharmaceuticals shares are trading lower after the company announced the commencement of an underwritten public offering.
Benzinga Newsdesk

Mon Aug 31, 2026

PMV Pharmaceuticals Announces Commencement Of Underwritten Public Offering Of Common Stock, Pre-Funded Warrants And Accompanying Warrants; Size And Terms Not Disclosed
Benzinga Newsdesk

Mon Aug 31, 2026

PMV Pharmaceuticals Says Interim Phase 2 PYNNACLE Data Show 46% Overall Response Rate In 76 Evaluable TP53 Y220C Ovarian Cancer Patients, Median Duration Of Response 10.0 Months; Plans NDA Submission In Q1 2027
Benzinga Newsdesk

Fri Aug 14, 2026

PMV Pharma Q2 EPS $(0.34) Beats $(0.39) Estimate

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 17.07 percent increase over losses of $(0.41) per share from the
Benzinga Insights

Wed May 13, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Newsdesk

Wed May 13, 2026

Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5

Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and lowers the price target from $6 to $5.
Benzinga Newsdesk

Tue May 12, 2026

PMV Pharma Q1 EPS $(0.34) Beats $(0.39) Estimate

PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is unchanged from the same period last year.
Benzinga Newsdesk

Wed Apr 22, 2026

PMV Pharmaceuticals Appoints Laurie Stelzer As Board Chair, Effective June 4, Succeeding Rich Heyman

PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced a leadership

BETR BETR $14.46 USD

LULU $100.57 USD

ALAB $310.56 USD

INTC $95.80 USD

NTLA $12.75 USD

MU $1,015.36 USD

MSTX MSTX $16.80 USD

ASML $1,714.70 USD

SNDK $1,738.83 USD